<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02641093</url>
  </required_header>
  <id_info>
    <org_study_id>UCCI-HN-15-01</org_study_id>
    <nct_id>NCT02641093</nct_id>
  </id_info>
  <brief_title>Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma</brief_title>
  <official_title>Phase II Investigation of Adjuvant Combined Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trisha Wise-Draper</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to test the safety and the benefit of adding
      pembrolizumab (a therapy that activates the immune system to fight cancer) to standard of
      care treatment for head and neck cancer. The standard of care treatment will include surgery
      followed by radiation for 6 weeks. Some patients may also receive cisplatin as standard of
      care once a week for 6 weeks if the cancer is found to be &quot;high risk&quot;. High risk includes
      cancer that was not completely removed (positive margins) or cancer that has invaded through
      the outer lining of your lymph nodes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment related adverse effects as assessed using CTCAE v4.0 of pembrolizumab when combined with radiation alone and chemoradiation</measure>
    <time_frame>30 days following completion of treatment</time_frame>
    <description>Compare percentage of grade 3 and 4 adverse events with historical control percentages.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease free survival in resected high risk patients treated with adjuvant pembrolizumab and chemoradiation</measure>
    <time_frame>1 and 3 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease free survival in resected intermediate risk patients treated with adjuvant pembrolizumab and radiation</measure>
    <time_frame>1 and 3 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor immune response to pembrolizumab as measured by immunohistochemistry in tumor tissue before and after treatment</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab in combination with standard of care surgery followed by radiation therapy with or without cisplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab administered one week prior to surgery and then every three weeks in the adjuvant setting for a total of 7 doses.</description>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>gross total surgical resection</description>
    <arm_group_label>Pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>60-66 Gy over 6 weeks</description>
    <arm_group_label>Pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Weekly during radiation therapy for 6 doses only for patients with high risk pathological features</description>
    <arm_group_label>Pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients eligible for resection with one or more of the following

               1. Any T stage with â‰¥ N2 disease;

               2. T4 disease, any N stage;

               3. T3 Oral Cavity, any N stage; or

               4. Clinical evidence of extra-capsular extension on scans.

          -  Must be willing to undergo definitive resection with neck dissection.

          -  Performance status 0 or 1 on Eastern Cooperative Oncology Group Performance Scale.

          -  Adequate labs

          -  Appropriate staging imaging.

        Exclusion Criteria:

          -  Diagnosis of immunodeficiency or receiving systemic steroid therapy or
             immunosuppressive therapy within 7 days prior to planned first dose of trial
             treatment.

          -  Nasopharyngeal or sinonasal carcinoma

          -  Confirmed metastatic disease

          -  Human Papillomavirus (HPV)+ disease of the oropharynx

          -  Known history of active tuberculosis (TB), autoimmune disease, pneumonitis, infection,
             HIV, Hepatitis B, or Hepatitis C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Trisha Wise-Draper, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>UC Cancer Institute Clinical Trials Office</last_name>
    <phone>513-584-7698</phone>
    <email>kastla@ucmail.uc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Worden, MD</last_name>
    </contact>
    <investigator>
      <last_name>Frank Worden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>UC Cancer Institute Clinical Trials Office</last_name>
      <phone>513-584-7698</phone>
      <email>kastla@ucmail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>Trisha Wise-Draper, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrina Banyas, BS</last_name>
      <phone>614-685-2127</phone>
      <email>Katrina.Banyas@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Old, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittanie Weinerman</last_name>
      <phone>843-792-6349</phone>
      <email>weinerma@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Paul O'Brien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2015</study_first_submitted>
  <study_first_submitted_qc>December 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2015</study_first_posted>
  <last_update_submitted>December 13, 2017</last_update_submitted>
  <last_update_submitted_qc>December 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Trisha Wise-Draper</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

